Targeting Runx1 in Pathological Retinal Angiogenesis: A Potential Therapeutic Approach

Area of Science:

• Ophthalmology
• Molecular Biology
• Genetics

Background:

• Neovascular eye diseases like PDR, wAMD, and ROP cause significant vision loss globally.
• RUNX1 is identified as a key regulator in the hypoxic response, crucial for vascular development.

Purpose of the Study:

• To investigate the role of RUNX1 in physiological and pathological retinal vasculature formation.
• To characterize the effects of Runx1 loss in endothelial cells on retinal vascular development.

Main Methods:

• RNA-seq and transcription factor motif enrichment analysis in HUVECs.
• Conditional deletion of Runx1 in mouse endothelial cells (Runx1iECKO mice).
• Assessment of vascular parameters, clinical sample analysis, and in vitro/in vivo experiments, including PI3K/AKT/mTOR pathway analysis.

Main Results:

• Loss of Runx1 reduced retinal vascular coverage, density, progression, branchpoints, and sprouts during development.
• RUNX1 was upregulated in patients with PDR and ROP.
• RUNX1 inhibition decreased pathological neovascularization by affecting endothelial cell proliferation, migration, and tubule formation via the PI3K/AKT/mTOR pathway.

Conclusions:

• Runx1 is essential for physiological retinal vascularization.
• Targeting RUNX1 may be a promising therapeutic strategy for inhibiting pathological neovascularization in retinal disorders.
• This approach could preserve mature blood vessels while selectively inhibiting abnormal growth.